First-Trimester Placental Growth Factor in Screening for Gestational Diabetes

Objective: The aim of this study was first to assess whether first-trimester serum concentrations of placental growth factor (PlGF) differ between patients with and without gestational diabetes (GDM) and second to test whether there is a correlation between glycosylated hemoglobin (HbA1c), a factor recently shown to be useful in predicting GDM, and PlGF. Methods: PlGF was measured at 8-14 weeks with the Kryptor Immunoassay Analyzer (Brahms, Berlin, Germany). Absolute values were converted to multiples of the median using the software provided by the Fetal Medicine Foundation London. GDM was diagnosed using internationally accepted criteria. HbA1c levels were quantified using the TOSOH G7 automated hemoglobin analyzer. Results: From January to December 2014, 328 women were included in the study, 51 (15.5%) of whom developed GDM. First-trimester PlGF quantification does not discriminate between women at risk to develop GDM and controls, while HbA1c is able to do so. No correlation was found between PlGF and HbA1c. Conclusion: Our findings do not lend support to the hypothesis that early PlGF values are different in women who later develop GDM.

Download Full-text

Predictive Value of First-Trimester Glycosylated Hemoglobin Levels in Gestational Diabetes Mellitus: A Chinese Population Cohort Study

Journal of Diabetes Research ◽

10.1155/2021/5537110 ◽

2021 ◽

Vol 2021 ◽

pp. 1-6

Author(s):

Jianbin Sun ◽

Sanbao Chai ◽

Xin Zhao ◽

Ning Yuan ◽

Jing Du ◽

...

Keyword(s):

Diabetes Mellitus ◽

Blood Glucose ◽

Gestational Diabetes ◽

Pregnant Women ◽

Predictive Value ◽

Statistical Difference ◽

Glycosylated Hemoglobin ◽

Fasting Blood Glucose ◽

First Trimester ◽

Hba1c Levels

This study was aimed at exploring the predictive value of first-trimester glycosylated hemoglobin (HbA1c) levels in the diagnosis of gestational diabetes mellitus (GDM). A total of 744 pregnant women registered at the Peking University International Hospital between March 2017 and March 2019 were included in this study. Data on personal characteristics and biochemical indicators of the pregnant women were collected during the first trimester. The International Association of Diabetes and Pregnancy Study Groups has adopted specific diagnostic criteria as the gold standard for the diagnosis of GDM. Receiver operating characteristic (ROC) curve statistics were used to assess the predictive value of first-trimester HbA1c levels in the diagnosis of GDM. HbA1c levels in the first trimester were significantly higher in the GDM group than in the non-GDM group ( 5.23 % ± 0.29 % vs. 5.06 ± 0.28 % , P < 0.05 ). The first-trimester HbA1c level was an independent risk factor for gestational diabetes. The area under the ROC curve (AUC) of HbA1c for GDM was 0.655 (95% confidence interval 0.620-0.689, P < 0.001 ). The positive likelihood ratio was the highest at HbA 1 c = 5.9 % , sensitivity was 2.78, and specificity was 99.83%. There was no statistical difference in AUC between fasting blood glucose and HbA1c ( P = 0.407 ). First-trimester HbA1c levels can be used to predict GDM. The risk of GDM was significantly increased in pregnant women with first ‐ trimester HbA 1 c levels > 5.9 % . There was no statistical difference between first-trimester HbA1c and fasting blood glucose levels in predicting GDM.

Download Full-text

Routine first‐trimester combined screening for pre‐eclampsia: pregnancy‐associated plasma protein‐A or placental growth factor?

Ultrasound in Obstetrics and Gynecology ◽

10.1002/uog.23669 ◽

2021 ◽

Author(s):

L. Nöel ◽

G. P. Guy ◽

S. Jones ◽

K. Forenc ◽

E. Buck ◽

...

Keyword(s):

Growth Factor ◽

Plasma Protein ◽

Protein A ◽

First Trimester ◽

Placental Growth Factor

Download Full-text

The Effect of Oat Bran Supplement on Fasting Blood Sugar and Glycosylated Hemoglobin in Patients with Gestational Diabetes Mellitus: Single-blind Randomized Clinical Trial

Journal of Nutrition and Food Security ◽

10.18502/jnfs.v4i1.395 ◽

2019 ◽

Author(s):

Maedeh Shahzeidi ◽

Azadeh Nadjarzadeh ◽

Masoud Rahmanian ◽

Amin Salehi Abarghuoei ◽

Hossein Fallahzadeh ◽

...

Keyword(s):

Diabetes Mellitus ◽

Clinical Trial ◽

Weight Gain ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Blood Sugar ◽

Glycosylated Hemoglobin ◽

Oat Bran ◽

Single Blind ◽

Hba1c Levels

Background: Gestational diabetes mellitus (GDM) is known as a degree of glucose intolerance that occurs for the first time during pregnancy. There is paucity of evidence regarding the effect of oat bran on GDM. Oat as a source of β-glucan can be effective in reducing the blood sugar levels. This study aimed to investigate the effect of oat bran on fasting blood sugar (FBS) and glycosylated hemoglobin (HbA1c) in patients with GDM. Method: This single-blind clinical trial was conducted on 90 pregnant women with GDM. The experimental group (EG) consumed 30 g of oat bran daily with 100 g of low-fat yogurt before lunch and dinner for 4 weeks. The control group (CG) consumed only low-fat yogurt and both groups received nutrition counseling. The present study investigated the FBS, HbA1c, and weight gain at the beginning and after four weeks of intervention. Results: Out of 90 patients, 80 completed the study. FBS decreased in the EG (P = 0.04, -2.75 ± 8.22), whereas, it increased in the CG (P = 0.003, 4.37 ± 8.72). No significant difference was observed between the two groups in terms of HbA1c levels. Weight gain was controlled more efficiently in the EG than the CG (P = 0.001). Conclusion: The use of oat bran for four weeks decreased the FBS,; whereas, it did not affect HbA1c levels. Weight gain was controlled better in the EG than the CG.

Download Full-text

Методика проведения скринингового исследования в первом триместре беременности с расчетом риска развития преэклампсии и задержки роста плода по алгоритму Фонда медицины плода (Fetal Medicine Foundation)

Ultrasound & Functional Diagnostics ◽

10.24835/1607-0771-2018-4-77-88 ◽

2018 ◽

pp. 77-88

Keyword(s):

Growth Factor ◽

Plasma Protein ◽

Protein A ◽

Placental Growth Factor ◽

Fetal Medicine

В статье представлено описание методики проведения раннего пренатального скрининга с расчетом индивидуального риска развития преэклампсии и задержки роста плода в 11+1–13+6 нед беременности, проводимого согласно алгоритму Фонда медицины плода (Fetal Medicine Foundation) одновременно со скринингом на наличие у плода синдромов Дауна, Эдвардса и Патау. Расчет индивидуального риска развития преэклампсии и задержки роста плода осуществляется с учетом материнских характеристик, среднего артериального давления, пульсационного индекса в маточных артериях, ассоциированного с беременностью протеина А (pregnancy-associated plasma protein-A (РАРР-А)) и плацентарного фактора роста (placental growth factor (PlGF)) в сыворотке матери. Представлена характеристика каждого из этих параметров в предсказательной оценке риска развития преэклампсии и задержки роста плода. Отражены диагностические возможности данного алгоритма и его преимущества над классическими системами формирования групп высокого риска по развитию преэклампсии, учитывающих только материнские характеристики. Ключевые слова: комбинированный скрининг первого триместра беременности, задержка роста плода, преэклампсия, среднее артериальное давление, пульсационный индекс в маточных артериях, ассоциированный с беременностью протеин А (РАРР-А), плацентарный фактор роста (PlGF).

Download Full-text